MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Vericel Corporation Operating Expenses 2011-2026 | VCEL
Annual Operating Expenses Vericel Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 195 M | 168 M | 142 M | 127 M | 114 M | 81.9 M | 91.5 M | 62.6 M | 48.6 M | 42.7 M | 41.4 M | 35 M | 21 M | 33.8 M | 29.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 195 M | 21 M | 82.2 M |
Quarterly Operating Expenses Vericel Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 46.1 M | 48.6 M | 49.1 M | - | 44.1 M | 42.6 M | 40.8 M | - | 35.7 M | 35.9 M | 34.7 M | - | 32 M | 31.9 M | 30.7 M | - | 27.1 M | 30.6 M | 26.3 M | - | 19 M | 19.7 M | 21.8 M | - | 18.1 M | 37.3 M | 16.5 M | - | 15.7 M | 15.5 M | 14.7 M | - | 11.1 M | 11.8 M | 11.9 M | - | 10.5 M | 10.5 M | 9.54 M | - | 9.41 M | 8.95 M | 9.85 M | - | 12.1 M | 7.94 M | 4.64 M | - | 3.64 M | 5.24 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 49.1 M | 3.64 M | 22.7 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Assembly Biosciences
ASMB
|
84.4 M | $ 28.46 | 3.45 % | $ 319 M |  USA |
 |
Ascendis Pharma A/S
ASND
|
338 M | $ 221.88 | -0.87 % | $ 5 B |  Danmark |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Axsome Therapeutics
AXSM
|
99.1 M | $ 156.92 | -1.23 % | $ 7.81 B | USA |
 |
Galera Therapeutics
GRTX
|
70.6 M | - | -32.59 % | $ 7.61 M | USA |
 |
Pharming Group N.V.
PHAR
|
98.4 M | $ 15.36 | -0.71 % | $ 7.59 B |  Niderland |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.37 | -4.2 % | $ 350 M |  Britain |
 |
Kamada Ltd.
KMDA
|
69 K | $ 8.5 | -1.39 % | $ 260 M |  Israel |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Benitec Biopharma
BNTC
|
9.83 M | $ 10.98 | -4.52 % | $ 452 M | USA |
 |
Inventiva S.A.
IVA
|
36.2 M | $ 5.78 | -4.3 % | $ 138 M | France |
 |
Compugen Ltd.
CGEN
|
40.4 M | $ 2.09 | -0.95 % | $ 195 M | Israel |
 |
Tiziana Life Sciences PLC
TLSA
|
15.8 M | $ 1.21 | -3.97 % | $ 71.5 M | Britain |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
PainReform Ltd.
PRFX
|
689 K | $ 2.28 | -0.44 % | $ 1.03 M | Israel |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
|
Foghorn Therapeutics
FHTX
|
117 M | $ 5.0 | 2.25 % | $ 315 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
AbCellera Biologics
ABCL
|
292 M | $ 3.4 | -3.68 % | $ 1.02 B | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
1.47 B | $ 54.13 | -1.64 % | $ 10.4 B | USA |
 |
Curis
CRIS
|
33.9 M | $ 0.77 | 1.89 % | $ 4.86 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
22.4 M | - | -74.18 % | $ 955 K | USA |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Coherus BioSciences
CHRS
|
231 M | $ 1.52 | -5.59 % | $ 178 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Burford Capital Limited
BUR
|
106 M | $ 7.7 | -5.87 % | $ 1.29 B | Britain |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Cellectis S.A.
CLLS
|
109 M | $ 3.34 | -4.02 % | $ 116 M | France |
 |
Arbutus Biopharma Corporation
ABUS
|
96.2 M | $ 4.24 | -2.97 % | $ 704 M | Canada |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cardiff Oncology
CRDF
|
49.6 M | $ 1.8 | -1.1 % | $ 120 M | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
Cabaletta Bio
CABA
|
74.7 M | $ 2.94 | -3.29 % | $ 3.43 M | USA |
 |
Iterum Therapeutics
ITRM
|
18.7 M | $ 0.16 | -5.45 % | $ 3.15 M |  Irlanda |
 |
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | USA |